Ovidiu Calapod

Dr. Ovidiu Calapod

Carol Davila University of Medicine and Pharmacy Bucharest - Faculty of Medicine, Bucharest, Romania

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2021 in Medicina
Verified
Journal Article
Open access
PDF file
OCOvidiu Calapod
Ovidiu Calapod
AMAndreea Maria Marin
Andreea Maria Marin
MOMinodora Onisai
Minodora Onisai
LTLaura Tribus
Laura Tribus
specialist Silviaspecialist Silvia
specialist Silvia
Carmen Fierbinteanu-BraticeviciCarmen Fierbinteanu-Braticevici
Carmen Fierbinteanu-Braticevici
Background: Emerging evidence suggests that patients with metabolic (dysfunction) associated fatty liver disease (MAFLD) are prone to severe forms of coronavirus disease (COVID-19), especially those with underlying liver fibrosis. The aim of our study is to assess the association of an increased FIB-4 score with COVID-19 disease prognosis. Methods: We performed a prospective study on hospitalized patients with known type II diabetes mellitus (T2DM) and confirmed COVID-19, with imaging evidence of liver steatosis within the last year or known diagnosis of MAFLD. All individuals were screened for liver fibrosis with a FIB-4 index. We evaluated the link between FIB-4 and disease prognosis. Results: Of 138 participants, 91.3% had MAFLD and 21.5% patients had a high risk of fibrosis. In the latter group of patients, the number of severe forms of disease, the hospital stay length, the rate of ICU admissions and the number of deaths reported registered a statistically significant increase. The independent predictors for developing severe forms of COVID-19 were obesity (odds ratio (OR), 3.24; 95% confidence interval (CI), p = 0.003), higher values of ferritin (OR-1.9; 95% CI, 1.17–8.29, p = 0.031) and of FIB-4 ≥ 3.25 (OR-4.89; 95% CI, 1.34–12.3, p = 0.02). Conclusions: Patients with high scores of FIB-4 have poor clinical outcomes and liver fibrosis may have a relevant prognostic role. Although the link between liver fibrosis and the prognosis of COVD-19 needs to be evaluated in further studies, screening for liver fibrosis with FIB-4 index, particularly in patients at risk, such as those with T2DM, will make a huge contribution to patient risk stratification.

29 July 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
OCOvidiu Calapod
Ovidiu Calapod
AMAndreea Maria Marin
Andreea Maria Marin
Anca StoianAnca Stoian
Anca Stoian
Carmen Fierbinteanu-BraticeviciCarmen Fierbinteanu-Braticevici
Carmen Fierbinteanu-Braticevici
Background and Objectives: Non-alcoholic fatty liver disease (NAFLD)-related severe liver fibrosis is associated with a higher risk of progressing to decompensated cirrhosis and hepatic failure and developing NAFLD-related hepatocellular carcinoma (HCC), particularly in populations with diabetes. Our pilot study aims to evaluate the performances of various noninvasive methods in predicting liver fibrosis in a population of patients with diabetes and to establish a new scoring system for the prediction of severe fibrosis (>F3). Materials and Methods: A total of 175 patients with diabetes were enrolled for liver fibrosis evaluation. Using the degree of agreement (concordance) between a noninvasive score based on serum biomarkers (NAFLD fibrosis score) and point shear-wave elastography (pSWE) as the reference method, we generated receiver operating characteristic (ROC) curves and performed a multivariate analysis to predict severe liver fibrosis. Results: In our population of patients with diabetes, gamma-glutamyltransferase (GGT), age, body mass index (BMI), the homeostatic model assessment of insulin resistance (HOMA-IR), and glycosylated hemoglobin (HbA1C) were significant predictors for the diagnosis of the F3/F4 group (area under the ROC: 0.767, 0.743, 0.757, 0.772, and 0.7, respectively; p < 0.005 for all). Moreover, the combined composite score (the sum of GGT, age, BMI, HOMA index, and HbA1C) had the highest diagnostic performance at a cut-off value of 3 (AUROC—0.899; p < 0001). The sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) were 91.20%, 79%, 79%, and 89%, respectively, and 89% of patients were correctly classified as having severe liver fibrosis. In contrast with the Fibrosis 4 (FIB-4) score and the AST-to-platelet ratio index (APRI), the composite score had the best accuracy in discriminating advanced fibrosis. Conclusions: The proposed composite score had a reliable and acceptable diagnostic accuracy in identifying patients with diabetes at risk of having severe fibrosis using readily available laboratory and clinical data.

1 December 2019 in Romanian Journal of Orthopaedic Surgery and Traumatology
Verified
Journal Article
Open access
PDF file
OCOvidiu Calapod
Ovidiu Calapod
AMAndreea Maria Marin
Andreea Maria Marin
LTLaura Carina Tribus
Laura Carina Tribus
CFCarmen Fierbinţeanu-Braticevici
Carmen Fierbinţeanu-Braticevici
Introduction. Sarcopenia is a common complication and a frequently encountered feature in liver cirrhosis. Also, sarcopenia is a strong prognosis factor and a predictor of mortality in patients with advanced liver disease. However, in clinical practice, there are no well-established criteria for the diagnosis of this common complication of cirrhosis, the mechanisms which are involved are poorly understood and the possible therapeutic options are still undergoing randomized clinical trials. Materials and methods. To summarize the actual understanding of sarcopenia in cirrhosis, a literature search was performed using PubMed, MedLine, and Web of Science, to find articles related to definition, physiopathology, and treatment of sarcopenia of these patients. Results. A number of 30 papers that were suitable for this review were found. Most of them concluded that sarcopenia is a strong predictor of mortality, has a higher risk of hepatic encephalopathy and an increased health related cost in cirrhotic patients. The factors involved in this condition are far more complex than malnutrition and reduced protein intake, and include metabolic switch to the use of amino acids and fats to produce glucose. According to actual guidelines, beside moderate physical exercise and BCAA intake, therapeutic intervention with testosterone and ammonia-lowering therapies might have the potential to reverse sarcopenia in cirrhosis. Conclusion. Improved understanding of factors such as underlying nutritional imbalances, amount of oral protein intake, dose, type and duration of supplementation and the compliance of physical exercise, should be the focus of further research with randomized controlled trials.